Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | GOT1 | P17174 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | SPR | P35270 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925617 | 0.93 | MAPT (0.87) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL26430695 | 0.89 | MAPT (0.83) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL23925547 | 0.88 | MAPT (0.78) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL23925546 | 0.85 | GOT1 (0.75) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL26430691 | 0.84 | MAPT (0.72) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL23925476 | 0.84 | MAPT (0.76) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL23925487 | 0.81 | MAPT (0.79) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL31543697 | 0.80 | MTNR1A (1.00) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL1771902 | 0.80 | MTNR1A (1.00) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B | |
| SCHEMBL23925504 | 0.79 | GOT1 (0.78) | MAPTSMN1; SMN2POLBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | claimed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | claimed |
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | MAPT 1718/4885SMN1; SMN2 4580/4885POLB 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.